You are here

Coronary Intervention & Surgery

 

Hospitals ranked in the top 50 for cardiology and heart surgery by U.S. News and World Report appear no better at performing PCI than unranked hospitals, according to an analysis of more than 500,000 procedures performed at 654 hospitals.

PCI of chronic total occlusions (CTOs) can be safely performed by expert operators and provides significant benefit to patients with reduced left ventricular ejection fraction (LVEF) or diabetes, according to a series of studies published Nov. 13 in JACC: Cardiovascular Interventions.

Scaffold discontinuity, malapposition and neoatherosclerosis were found to be the leading mechanisms behind very late scaffold thrombosis (VLScT) in cardiac patients implanted with bioresorbable devices, investigators from the INVEST registry have reported.

Recent studies have shown robotic PCI to be a feasible way to treat coronary artery disease. But at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 30, Ryan D. Madder, MD, took the conversation a step further: Will it eventually be possible to perform “tele-stenting” over long distances?

Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.

 

Recent Headlines

Emerging surgical techniques shown to reduce heart surgery complications

A new study reports that emerging surgical techniques used to perform more extensive surgical repairs of type A dissection is improving long-term outcomes for patients.

The dawn of rejecting rejection?

Englishman John McCafferty holds the record as the world's longest surviving heart transplant patient. At the time of his surgery in the fall of 1982, physicians estimated he’d live five years. He lived another 30 on top of that—working, enjoying family, running half marathons, traveling, fundraising for a transplant support charity and trout fishing—before passing away just last summer.

FDA approves expanded use of Sapien 3 heart valve

The U.S. Food and Drug Administration (FDA) approved an expanded indication for the Sapien 3 Transcatheter Heart Valve, a move that will allow physicians to use the device to better treat patients with symptomatic heart disease.

Detroit hospital treats first high-risk patient with Tryton stent

St. John Hospital & Medical Center became the first facility in the United States to treat a high-risk patient with a heart pump and newly approved Tryton Side Branch Stent.

New research suggests not all heart attack patients benefit from beta blockers

New research from the University of Leeds in the United Kingdom challenges the established practice that all heart attack patients should be administered beta blockers to decrease heart activity and lower blood pressure.

Boston Scientific’s TAVI system exceeds expectations in clinical trial

Boston Scientific’s transcatheter aortic valve implantation (TAVI) technology, the LOTUS Valve System, shows superiority to a similar platform made by a competitor in a new clinical trial.

SCAI 2017: TAVR outcomes depend on individual risk factors, not valve type

A late-breaking study, presented May 12 at the Society of Cardiovascular Angiography and Interventions meeting in New Orleans, showed that factors related to individual patients—and not the specific type of valve used—determined 30-day outcomes for transcatheter aortic valve replacement (TAVR).

SCAI 2017: Robotic PCI highly successful with transradial, transfemoral access

The May 12 late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans compared femoral and radial robotic percutaneous coronary intervention (PCI) procedures.

Researchers reduce donor heart rejection with desensitizing antibodies

On the 50th anniversary of using heart transplantation to save lives, researchers from the Pitié-Salpêtrière Hospital in Paris revealed a technique that could reduce the risk of patients rejecting donor hearts.

Patients with degenerative mitral valve disease see better results with experienced surgeons

A database analysis in New York found that the mitral valve case volume of individual surgeons had a significant impact on patient outcomes following surgery.

Pages